Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Small PEGs

Over the past decade, Nektar Therapeutics' pegylation capabilities have provided a growing royalty stream via third party sales of biologics that use the technology. Now, internal products that use the pegylation technology are starting to gain visibility. The twist is that NKTR is developing pegylated small molecules.

NKTR opted not to

Read the full 507 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers